VolitionRx (NYSE:VNRX) Issues Earnings Results

VolitionRx (NYSE:VNRX) posted its earnings results on Monday. The company reported ($0.11) earnings per share for the quarter, Zacks reports. The business had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.50 million. VolitionRx had a negative net margin of 4,557.29% and a negative return on equity of 7,185.73%.

VolitionRx Trading Down 3.0 %

NYSE:VNRX traded down $0.02 during trading hours on Wednesday, hitting $0.73. The stock had a trading volume of 192,460 shares, compared to its average volume of 184,538. VolitionRx has a one year low of $0.55 and a one year high of $2.10. The company has a debt-to-equity ratio of 0.56, a quick ratio of 0.69 and a current ratio of 0.69. The company has a market cap of $57.25 million, a price-to-earnings ratio of -1.45 and a beta of 1.38. The business’s 50 day moving average is $1.00 and its 200-day moving average is $0.87.

Analyst Ratings Changes

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $2.50 price objective on shares of VolitionRx in a research note on Wednesday.

Institutional Investors Weigh In On VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Vanguard Group Inc. raised its position in VolitionRx Limited (NYSE:VNRX) by 4.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 542,444 shares of the company’s stock after purchasing an additional 22,046 shares during the period. Vanguard Group Inc. owned approximately 0.69% of VolitionRx worth $374,000 as of its most recent filing with the SEC. Institutional investors own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 worldwide. It offers Nu.Q Vet cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer that detect cancer; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes.